Interplay between β-lactamases and new β-lactamase inhibitors

Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae

(2018) Martin Everett et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Efficacy of Meropenem, with a novel non-β-lactam β-lactamase Inhibitor, Nacubactam, against Gram-negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

(2018) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and management of pediatric sinusitis: A survey of primary care, otolaryngology and urgent care providers

(2018) Laurie Newton et al.   INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

(2018) Keith S. Kaye et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

(2018) James A Karlowsky et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli

(2018) Lisa M. Schechter et al.   mBio

Past and Present Perspectives on β-Lactamases

(2018) Karen Bush   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, 2012 to 2015

(2018) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

(2017) David M Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Piperacillin–tazobactam as alternative to carbapenems for ICU patients

(2017) Benoit Pilmis et al.   Annals of Intensive Care

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

(2017) Adam B. Shapiro et al.   ACS Infectious Diseases

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

(2017) Thomas F. Durand-Réville et al.   Nature Microbiology

AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling

(2017) Krisztina M Papp-Wallace et al.   Open Forum Infectious Diseases

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

(2016) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations

(2016) Sushmita D. Lahiri et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080

(2016) M. Doumith et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

(2015) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoActivities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae

(2015) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

(2015) Douglas J. Biedenbach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2015) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization ofEscherichia coliNDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3

(2015) Richard A. Alm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’

(2015) Akihiro Morinaka et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

(2015) Scott J. Hecker et al.   JOURNAL OF MEDICINAL CHEMISTRY

Facing the challenge of multidrug-resistant gram-negative bacilli in Australia

(2015) Patrick Harris et al.   MEDICAL JOURNAL OF AUSTRALIA

The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide

(2014) P. Nordmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

OXA  -Lactamases

(2014) B. A. Evans et al.   CLINICAL MICROBIOLOGY REVIEWS

Genetic Characterization and Emergence of the Metallo-β-Lactamase GIM-1 in Pseudomonas spp. and Enterobacteriaceae during a Long-Term Outbreak

(2013) Andreas F. Wendel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

(2013) Sarah M. Drawz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metallo-β-lactamase structure and function

(2012) Timothy Palzkill   Annals of the New York Academy of Sciences

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OXA-48-like carbapenemases: the phantom menace

(2012) L. Poirel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTX-M Enzymes: Origin and Diffusion

(2012) Rafael Cantón et al.   Frontiers in Microbiology

In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trends in antimicrobial resistance in intensive care units in the United States

(2011) Kavitha Prabaker et al.   Current Opinion in Critical Care

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

False extended-spectrum β-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins

(2011) Alejandro Beceiro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

Inhibitor Resistance in the KPC-2  -Lactamase, a Preeminent Property of This Class A  -Lactamase

(2009) K. M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diversity, Epidemiology, and Genetics of Class D  -Lactamases

(2009) L. Poirel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Updated Functional Classification of  -Lactamases

(2009) K. Bush et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of a New Metallo- -Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India

(2009) D. Yong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AmpC  -Lactamases

(2009) G. A. Jacoby   CLINICAL MICROBIOLOGY REVIEWS

Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of β-Lactamases

(2009) Hilary Frase et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated  -lactamase production and OmpK36 porin deficiency

(2009) X. D. Wang et al.   JOURNAL OF MEDICAL MICROBIOLOGY

IRT and CMT β-lactamases and inhibitor resistance

(2008) R. Cantón et al.   CLINICAL MICROBIOLOGY AND INFECTION

Minor extended-spectrum β-lactamases

(2008) T. Naas et al.   CLINICAL MICROBIOLOGY AND INFECTION